AI Trends

Isomorphic Labs Completes $5 Billion Series C Funding, Setting a New Record for a Single AI Drug Discovery Financing Round

East MoneyUpdated Nov 18 11:03

AI summary

Isomorphic Labs, an AI drug discovery company under Alphabet, announced on November 17 that it had completed a $5 billion Series C funding round, co-led by Greenoaks and Sequoia Capital, with a16z newly participating, and with all existing shareholders including Alphabet, Thrive Capital, MGX, GV, Temasek, and the UK Sovereign AI Fund following on, setting a new global record for a single AI drug discovery financing round. Spun out of Google DeepMind, the company has Demis Hassabis as CEO and has developed its own AI drug design engine, IsoDDE, pursuing an end-to-end generative drug discovery approach combining large models and agents. Currently, it has no candidate drug in clinical trials; this round of funding will go toward iterating the IsoDDE model, exploring new biological mechanisms, advancing internal proprietary pipelines, and building the partner ecosystem.

Why read this

AI score 60

Beyond the scale of the financing and the lineup of investors, the original text also notes the contrast that no candidate drug has yet entered clinical trials, making it easier to gauge the gap between capital enthusiasm for AI drug discovery and actual validation progress.

Topics

Tags

Body · AI translation

Article body

On November 17 local time, Isomorphic Labs, an AI drug discovery company under Google parent company Alphabet, officially announced the completion of a $5 billion (approximately RMB 33.3 billion) Series C funding round. The round was oversubscribed and set a new record for the largest single funding round in the global AI pharmaceutical industry.

The round was co-led by Greenoaks and Sequoia Capital, with Andreessen Horowitz (a16z) participating as a new investor; Alphabet continued to make a large additional investment, and all existing shareholders including Thrive Capital, MGX, GV, Capital G, Temasek, and the UK Sovereign AI Fund continued to follow on.

It is worth noting that although it has reached major new drug R&D collaborations with multinational pharmaceutical companies such as Eli Lilly, Novartis, and Johnson & Johnson, Isomorphic Labs currently has no candidate drug that has entered clinical trials.

Why is a pharmaceutical company with no drug yet clinically validated favored by so many star investors?

Isomorphic Labs was spun out of Google DeepMind and founded in February 2021, headquartered in London, with offices in Cambridge and Lausanne. It is an independently operated AI new drug R&D entity within the Alphabet system, with Demis Hassabis, co-founder of Google DeepMind, serving as CEO. Hassabis won the 2024 Nobel Prize in Chemistry for his research on protein structure prediction using the AI model AlphaFold2.

Demis Hassabis

The company's President Max Jaderberg also comes from DeepMind. Its core executive team brings together talent in AI basic research, computational biology, medicinal chemistry, and clinical development and commercialization, including Chief Scientific Officer Miles Congreve and Chief Medical Officer Ben Wolf, both senior pharmaceutical R&D leaders. The team is composed of machine learning scientists, structural biologists, medicinal chemists, and translational medicine experts.

In addition, its scientific advisory board brings together multiple Nobel laureates, including CRISPR gene editing pioneer Jennifer Doudna, chemist David MacMillan, as well as Paul Nurse and Venki Ramakrishnan.

Isomorphic Labs' technological foundation stems from the AlphaFold protein structure prediction breakthrough, but it has not stopped at protein structure analysis. It has self-developed the AI drug design engine IsoDDE, taking an end-to-end generative drug R&D route of "large models + intelligent agents."

Unlike most AI pharmaceutical companies that use AI only for single-point auxiliary tasks such as target screening and molecular docking, IsoDDE integrates multiple sets of AI models and can operate natively across multiple therapeutic areas and drug modalities, attempting to precisely simulate biological behavior at the molecular level.

This means that the platform can use AI agents to autonomously explore vast chemical spaces, simultaneously evaluate molecular druggability, selectivity, and toxicity risk, cover multiple drug modalities such as small molecules and antibodies, and span multiple therapeutic areas such as oncology and immunology, thereby designing molecules with ideal drug-like properties.

In the latest funding announcement, he said that based on IsoDDE, the R&D team can achieve reproducible scientific progress every week, and these advances directly translate into better molecular characteristics that are expected to become new drugs and solve some of the most difficult problems in drug R&D.

Looking back at the company's funding history, Isomorphic Labs completed its first external funding round in March 2025, raising $600 million, led by Thrive Capital with participation from Alphabet and GV; in May 2026, the company closed a $2.1 billion Series B round, which at the time also set a new high for a single funding round in the AI pharmaceutical field, with new sovereign capital and globally renowned growth funds including Temasek, MGX, and the UK Sovereign AI Fund joining, further expanding its investor lineup.

This round of $5 billion will focus on IsoDDE model iteration, discovery of new biological mechanisms, advancement of internal proprietary pipelines, and building a partner ecosystem. At the same time, Isomorphic Labs is building the global infrastructure needed to support the future of AI-driven bioengineering and to advance its drug candidates into clinical trials.

From the industry's current situation, technology companies including Google, Microsoft, OpenAI, and Anthropic have all entered the life sciences field; large pharmaceutical companies such as Eli Lilly have chosen to cooperate with AI pharmaceutical companies; and AI biotechnology companies such as Fauna Bio, Blank Bio, and Twist Bio continue to make new progress.

The institution further stated that the "computing power-model-wet lab data" iron triangle depicts the full landscape of the AI pharmaceutical industry chain. Computing power forms the foundation of AI pharmaceutical R&D, vertical models form the technical core, and wet lab data, as the rate-limiting step, has become the current core of competition. Upstream segments such as life science tools, protein expression, high-throughput validation, and preclinical CRO are expected to be the first to realize the logic and performance.

Huaxin Securities stated that at present, those laying out AI4S are mostly overseas large-model companies, but enterprises in the validation services industry chain with complete Gene-to-Protein capabilities are mainly concentrated in China, and leading companies are actively responding by expanding supporting capacity to take on more overseas orders. AI development is expected to accelerate new drug R&D, driving increased demand for wet lab validation, with orders increasing quarter by quarter.

(Source: Cailian Press) Middle of the body: embedded advertisement

Source

East Money